Both acute and chronic graft-versus-host disease, while fairly common in allogeneic HSCT, can be potentially fatal. The clinical manifestations of this complication can linger for years and often times impair quality of life drastically. Hematology and oncology specialists can optimize care by early recognition and prompt initiation of systemic therapies.

Pharmacists should be aware of data on targeted therapy and immunotherapy for RCC and be able to make appropriate therapy recommendations. In addition, pharmacists play an important role in the management of toxicity of targeted therapy or immunotherapy and encouraging compliance for patients on targeted therapies for RCC.

Pediatric ALL is a potentially curable malignancy and systemic therapy is the mainstay of treatment. Understanding the diagnosis, workup, and subsequent treatment of this disease will help clinicians play an important role in providing medication-related recommendations, supportive care, and patient counseling which can improve the outcomes and the quality of patient care.

Although considerable progress has been made in identifying supportive care issues in HCT survivors, large, prospective trials demonstrating the effectiveness of supportive care interventions for HCT-related complications are needed to guide future development of evidence-based guidelines. Importantly, because long-term HCT recipients may no longer be followed by transplant centers, recommendations for supportive care should be geared toward community healthcare providers who may not routinely care for HCT recipients.

Management of pediatric patients with cancer is complex and requires multidisciplinary coordination to organize cancer treatment and supportive care during treatment. In addition, care coordination is essential during the survivorship and end-of-life phases of pediatric cancer treatment.

The new combination immunotherapy + chemotherapy regimens represent a major change in systemic therapy for patients with metastatic NSCLC. Case managers and other health care providers have less experience with these new immunotherapy + chemotherapy regimens or the newer targeted therapies that have different mechanisms of action and side effects than traditional cytotoxic chemotherapy regimens.

To ensure safe access to opioid pain medications for patients with cancer, all members of the healthcare team need to understand the benefits of opioids, how to navigate the federal and state programs regulating opioid use, and how to develop strategies to prevent opioid misuse.